- Home
- STIM vs CNTB Comparison
STIM vs CNTB Comparison
Compare STIM & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STIM | CNTB |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.3M | 157.1M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STIM | CNTB |
|---|---|---|
| Price | $1.35 | $2.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.00 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 2.1M | 667.5K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $129,873,000.00 | $762,000.00 |
| Revenue This Year | $101.67 | N/A |
| Revenue Next Year | $10.87 | $38,289.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 78.61 | N/A |
| 52 Week Low | $1.00 | $0.51 |
| 52 Week High | $5.92 | $3.28 |
Technical Indicators
Market Signals| Indicator | STIM | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 30.82 | 51.59 |
| Support Level | $1.28 | $2.52 |
| Resistance Level | $1.51 | $2.87 |
| Average True Range (ATR) | 0.18 | 0.33 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 12.82 | 28.42 |
Price Performance
Historical ComparisonAbout STIM Neuronetics Inc.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.